PTEN and prostate carcinoma: Moreover, PTEN loss has been shown to cooperate with other oncogenic events to accelerate prostate cancer progression in vivo in a dose-dependent manner, and heterozygous loss of PTEN has been shown to accelerate prostate cancer progression in some clinical datasets [22,76,79,95,96,97].